- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix
The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma.
"We're very pleased to receive Fast Track status for DNX-2401 and are pleased that the FDA supports our position that there is an urgent need for additional therapies to treat glioblastoma," said Dr. Frank Tufaro, president and chief executive officer of DNAtrix. "Fast Track status reinforces our goal to quickly move forward with the development of DNX-2401. Recurrent glioblastoma is extremely challenging to treat, and clinical results from DNX-2401 to date indicate that the drug may be an important treatment option for the disease."
Press release: http://on.mktw.net/1nNoVCs
Source: MarketWatch
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
